EAVI2020 EAVI2020 on Twitter EAVI2020 on Facebook EAVI2020 on LinkedIn



We wanted to provide a quick update on how EAVI2020 is progressing at the moment in regard to COVID-19. We are living in an unprecedented and constantly changing period. The extraordinary measures in place to contain the spreading of the coronavirus and assuring the safety of everyone is impacting our lives, and our work in many ways. To further ensure the safety and well-being of all, EAVI2020 clinical studies have been placed on hold.
This is not an isolated circumstance, many research programmes across Europe are also in similar situations and are impacted by the containment measures.
We are closely and constantly monitoring the situation. At the moment there is uncertainty on when and how our suspended activities will resume however the EAVI2020 consortium continue to work out mitigating measures.
We will provide another update when there are any changes.
For further information, the European Commission has placed up-to-date information on their website regarding COVID-19 response and action.
Keep safe and well,
All the best,
Prof Robin Shattock
EAVI2020 coordinator and on behalf of the EAVI2020 consortium
Imperial College London

Welcome to the EAVI2020 project!

EAVI2020 is a 23 million euro initiative to accelerate the search for an effective HIV vaccine.

Vaccines are the most powerful public health tools available. Developing safe, effective and affordable vaccines that can prevent HIV infection in uninfected people is the best hope for controlling and ultimately ending the HIV epidemic. Developing a therapeutic vaccine could also be beneficial for people living with HIV by helping slow the progression of the disease and prevent or delay the onset of AIDS. Scientists in this consortium are pooling their expertise to make this possible.

Bienvenue dans le projet EAVI!

EAVI2020 est une initiative de 23 million d’euros pour accélérer la recherche d’un vaccin contre le VIH.

Les vaccins sont l’outil de santé publique le plus puissant au monde. Développer un vaccin sûr, efficace et abordable, qui protègerait d’une infection par le VIH est la meilleure solution pour mettre un terme à l’épidémie causée par ce virus. Le développement d’un vaccin thérapeutique pourrait également être bénéfique pour les personnes infectées vivants avec le VIH, en prevenant ou ralentissant l’apparition du SIDA. Les scientifiques de ce consortium rassemblent leurs expertises pour rendre cela possible.

Latest News

EAVI2020 May…
Download the May 2020 newsletter (.pdf opens in new tab) ...

EAVI2020 February 2020…
Read the EAVI2020 Newsletter February 2020 In this issue ...

wall of books
EAVI2020 Students in…
Let’s meet Philipp Mundsperger. [caption id="attachment_1...